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license (http://creativechanges in the retina (i.e., reduced thicknesses of the ganglion cell and retinal nerve fiber layers and
inclusion bodies that appear to contain beta-amyloid protein [Ab]) have been previously reported. We
sought to explore whether anatomic retinal changes are detectable in the preclinical stage of AD.
Methods: A cross-sectional study (as part of an ongoing longitudinal cohort study) involving 63
cognitively normal adults, all of whom have a parent with AD and subjective memory complaints.
We compared neocortical amyloid aggregation (florbetapir PET imaging) to retinal spectral domain
optical coherence tomography (SD-OCT) markers of possible disease burden. Retinal biomarkers,
including the number and surface area of retinal inclusion bodies and the thickness of retinal neuronal
layers, were compared across groups with high vs. low neocortical beta-amyloid load.
Results: The surface area of inclusion bodies increased as a function of cortical amyloid burden.
Additionally, there was a trend toward a selective volume increase in the inner plexiform layer
(IPL; a layer rich in cholinergic activity) of the retina in Ab1 relative to Ab2 participants, and
IPL volume was correlated with the surface area of retinal inclusion bodies.
Discussion: These initial results suggest that retinal imaging may be a potential cost-effective and
noninvasive technique that can be used to identify those at-risk for AD. Layer-specific changes in
the IPL and their association with surface area of inclusion bodies are discussed as a possible reflec-
tion of early inflammatory processes associated with cholinergic disruption and concurrent Ab accu-
mulation in the neocortex.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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commons.org/licenses/by-nc-nd/4.0/).Alzheimer’s disease (AD) is a complex neurodegenera-
tive process with multiple known and suspected etiologies,
with the disease having variable phenotypic presentations
[1]. Notwithstanding, there is now consensus that abnor-
mally high levels of cerebral beta-amyloid (Ab) indicate
AD pathology in individuals with clinically classified de-
mentia or mild cognitive impairment (MCI) [2–5]. Recentimer’s Association. This is an open access article under the CC BY-NC-ND
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using positron emission tomography (PET) scans [6]. These
studies have prospectively documented that cognitively
normal (CN) older adults who have high levels of cerebral
beta-amyloid (Ab1) have an increased rate of decline in
cognitive function, particularly in episodic memory, when
compared with CN older adults with low or normal levels
of cerebral beta-amyloid (Ab2) [7–10]. This decline in
cognitive function is often subtle (e.g., approximately
0.3–0.4 standard deviations per year on standard tests of
episodic memory), such that individuals, their caregivers,
or both are often unaware of the progressive deterioration
in memory [11,12]. This finding has led to consensus
from researchers and regulators for the classification of a
preclinical AD disease stage that precedes MCI or AD by
several years, with this period becoming a target for
therapeutic interventions (i.e., secondary prevention trials)
designed to intervene earlier in the disease progression by
slowing the aggregation of Ab [13].
Recently, the US Food and Drug Administration
approved three fluorine-18 labeled PET radiopharmaceuti-
cals (florbetapir, flutemetamol, and florbetaben) for identifi-
cation of cerebral amyloid burden in clinical settings.
Although the cost of PET imaging remains very high
(z$5000 USD), an increasing number of CN older adults
are motivated to participate in current and planned second-
ary prevention trials if they meet diagnostic criteria for pre-
clinical AD [13]. Moreover, as novel therapeutics are
advanced to slow progression of the disease, it will become
increasingly important to identify point-of-care clinical
markers of early disease burden, to determine (at lower
cost) which individuals should be referred for Ab PET imag-
ing [14]. Although age and apolipoprotein ε4 (APOE ε4) are
reliable risk factors for Ab1, there remain no clinical or
behavioral markers that can reliably detect risk for Ab1
within periods of ,18 months.
There is growing evidence that anatomic changes in the
retina may provide an opportunity for identifying and
quantifying central nervous system (CNS) amyloid levels.
When compared with healthy age-matched controls, pa-
tients with AD had reduced numbers of ganglion cell axons
and were three times more likely to have increased optic
nerve cup-to-disc ratio, a potential consequence of gan-
glion cell and nerve fiber loss [15]. Furthermore, peripapil-
lary retinal nerve fiber layer (RNFL) thickness has been
documented to be significantly thinner (suggestive of optic
atrophy) in patients with MCI and mild-to-moderate AD
when compared with age-matched controls [16–18]. In
addition to thinning of the peripapillary RNFL,
individuals with AD have corresponding thinning of the
macular RNFL [16]. Berisha et al. also have observed nar-
rowing of retinal veins, with decreased blood flow, in
patients with early AD as compared to healthy age-
matched controls [19].
Age-related macular degeneration (AMD) and AD are
both age-related neurodegenerative diseases, which shareseveral risk factors including cigarette smoking, hyperten-
sion, and hyperlipidemia, and histopathologic features
involving oxidative stress, inflammation, and complement
activation [20–23]. Like AD, which has Ab deposition in
the senile plaques, AMD has characteristic Ab deposition in
retinal drusen. Retinal drusen are typically located in the
outer retina, at the level of the retinal pigment epithelium
(RPE) and Bruch’s membrane [21,22]. It is important to
ensure that the Ab deposition in AD can be differentiated
from the retinal drusen of AMD that may also contain
amyloid. Accordingly, all multicolor and OCT images were
evaluated by a neuro-ophthalmologist (L.N.J.) to screen for
hyperflourescent drusen at the RPE level.
Most studies to date have been cross-sectional comparisons
of healthy controls and those with MCI or AD burden. Given
that peripapillary and macular RNFL thinning are accelerated
with chronological age, there could be considerable overlap
and difficulty in differentiating between pathologic changes in
RNFL thickness changes from normal age-related decline in
RNFL thickness [24]. Moreover, there is a paucity of data
describing longitudinal changes over time within the same sub-
jects with respect to the retinal layers, the retinal microvascula-
ture, and the aggregation of inclusion bodies that may
contain fibrillar Ab from the earliest, preclinical stage of AD
[25,26]. Herein, we describe baseline spectral domain optical
coherence tomography (SD-OCT) retinal imaging results from
an ongoing longitudinal natural history study of individuals
who are at high risk for the earliest, preclinical stage of AD.1. Methods
1.1. Participants
A total of 63 adults, ranging in age from 55 to 75 years,
with two well-established risk factors for AD, namely, a
self-reported first-degree family history of the disease, as
well as self-identification of subjective memory concerns,
were recruited using a selection process described previ-
ously [27]. All participants underwent a detailed medical
screening interview. Exclusion criteria were a diagnosis of
MCI or AD, history of neurological or psychiatric disorder,
any significant systemic illness or unstable medical condi-
tion (e.g., active cardiovascular disease), and current use
of any medications known to affect cognition (e.g., use of
sedative narcotics). Subjects with histories of cataract sur-
gery, corneal LASIK surgery, AMD, glaucoma, or subjects
with known ophthalmic pathology were excluded. In addi-
tion, multicolor imaging (topographical three-wavelength;
available through the SPECTRALIS system used in this
study) was obtained on all subjects, and these images
were reviewed by a neuro-ophthalmologist with ophthal-
mology board certification (L.N.J.) at the time that all Blue-
Peak autofluorescence (BAF) imaging data were scored.
Inclusion criteria were a score on the mini-mental state
examination (MMSE). 27 and performance within normal
limits on a battery of cognitive tests described previously
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independently, most were engaged in full-time or part-
time employment, and many were caretakers for a parent
with AD. Ab status and APOE genotype were unknown at
the time of assessment and were not used to determine
enrollment. Although Ab status and APOE genotyping
were conducted as a part of the study protocol, researchers
remained blinded to these results throughout testing. The
study was approved by and complied with the regulations
of Rhode Island Hospital’s Institutional Review Board,
and all participants provided written informed consent in
accordance with the Declaration of Helsinki. The study
complied with HIPAA regulations.
1.2. Procedure
Participants completed baseline clinical and neuropsy-
chological assessment involving neuropsychological tests
(Table 1) which assessed visuospatial learning and reasoning
(Groton maze learning test [GMLT]) [29,30], verbal
memory (International Shopping List Test) [31], visual
memory (Cogstate One-Card Learning [OCL] task) [28]
and working memory (Cogstate One Back [OBK] task)
[28]. The MMSE was used to assess general cognitive func-
tion, and participants’ mood was measured using the 15-item
Geriatric Depression Scale and the Depression, Anxiety and
Stress Scale (DASS). Subjective memory impairment was
determined using the memory complaint questionnaire. All
measures were performed by trained staff supervised by a
neuropsychologist.Table 1
Demographic and clinical characteristics
Variable Main outcome
Full sample (n 5
N (%)
Sex No. of female 39 (61.9%)
APOE No. of ε4 carriers 29 (46.8%)
Mean (SD)
Age No. of years 62.79 (5.35)
Education No. of years 17.21 (2.77)
SUVr (Neocortex) Standardized uptake value ratio 0.98 (0.16)
GDS Total score 1.86 (2.16)
DASS depression subscale Total depression subscale score 3.56 (6.70)
DASS anxiety subscale Total anxiety subscale score 2.73 (4.53)
DASS stress subscale Total stress subscale score 6.73 (6.77)
MAC-Q Total score 24.92 (3.57)
MMSE Total score 29.05 (1.02)
GMLT (moves/second) Total correct moves per second 0.81 (0.20)
GMLT (total errors) Total no. of errors 61.33 (18.38)
GMLT composite Standardized z-score 0.00 (0.80)
ISLT total recall Total words recalled 25.59 (4.22)
One-card learning task Accuracy of performance 1.01 (0.10)
One back task Accuracy of performance 1.45 (0.11)
Abbreviations: APOE, apolipoprotein; SUVr, standardized uptake value ratio;
Scale; MAC-Q, memory complaints questionnaire; MMSE, mini mental state exa
List Task.
NOTE. Bolded values are significant at the P , .001 level.Enrolled participants then completed SD-OCT imag-
ing, APOE genotyping from collected saliva samples,
and Ab PET imaging within 6 weeks of their baseline en-
try visit.
1.3. Measures1.3.1. APOE genotyping
A 2-mL saliva sample was collected from all participants
and sent for APOE genotyping at the Providence Veterans
Administration Hospital laboratory. Although this was
completed as part of the study, the resulting group sample
sizes were too small for subsequent statistical analysis.
Therefore, APOE genotype was not included as a factor in
subsequent analyses.
1.3.2. Ab PET imaging
To assess neocortical amyloid burden, all participants had
an Ab PET scan. A 370MBq (10 mCi1/2 10%) bolus injec-
tion of 18F-florbetapir was administered intravenously.
Approximately 50 minutes post-injection, a 20-minute PET
scan was performed with head CT scan for attenuation correc-
tion purposes. Images were obtained using a 128! 128matrix
and reconstructed using iterative or row action maximization
likelihood algorithms. PET standardized uptake value (SUV)
data were summed and normalized to the whole cerebellum
SUV, resulting in a region-to-cerebellum ratio termed SUV ra-
tio (SUVr). An SUVr threshold of 1.1 was used to discrimi-
nate between Ab2 and Ab1. Table 1 provides between-group63) Ab1 (n 5 10) Ab2 (n 5 53)
P Cohen’s d (95% CI)N (%) N (%)
31 (58.5%) 8 (80.0%) .199 —
22 (41.5%) 7 (70.0%) .108 —
Mean (SD) Mean (SD) P
62.28 (5.15) 65.50 (5.87) .081 20.56 (21.23 to 0.13)
17.18 (2.47) 17.40 (4.17) .819 20.06 (20.73 to 0.62)
1.27 (0.22) 0.93 (0.07) .000 3.20 (2.28–4.03)
1.91 (2.27) 1.60 (1.51) .685 0.19 (20.49 to 0.86)
3.73 (7.24) 2.70 (2.58) .660 0.28 (20.40 to 0.96)
2.87 (4.75) 2.00 (3.27) .585 0.25 (20.43 to 0.92)
6.65 (7.18) 7.10 (4.23) .850 20.09 (20.77 to 0.58)
24.92 (3.64) 24.90 (3.31) .984 0.01 (20.67 to 0.68)
29.13 (0.96) 28.60 (1.26) .132 0.43 (20.25 to 1.11)
0.78 (0.20) 0.81 (0.19) .540 20.16 (20.83 to 0.52)
59.87 (23.35) 61.79 (16.80) .726 20.10 (20.78 to 0.57)
0.02 (1.00) 20.01 (0.75) .919 0.04 (20.64 to 0.71)
24.73 (4.46) 25.85 (4.16) .374 20.26 (20.94 to 0.41)
0.95 (0.09) 1.02 (0.10) .011 20.72 (21.39 to 20.01)
1.40 (0.14) 1.46 (0.10) .063 20.54 (21.24 to 0.13)
GDS, Geriatric Depression Scale; DASS, Depression, Anxiety, and Stress
mination; GMLT, Groton maze learning test; ISLT, International Shopping
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SUVr (averaged over six regions of interest) [32]. These
SUVr calculations were performed using the MIMneuro soft-
ware, with a normative database of 74 healthy normal individ-
uals (48 males, 26 females), aged between the ages of 18–50
years, who all had negative amyloid scans onvisual assessment
[32]. For all cases, Ab positivity was confirmed by consensus
over-read by two board-certified radiologists who were also
board certified in nuclear medicine.
1.3.3. SD-OCT & BAF imaging
Participants were administered two drops of tropica-
mide (Mydriacyl 1%) per eye for pupil dilation before
OCT imaging. The Heidelberg SPECTRALIS SD-OCT
was used to acquire retinal OCT scans of the optic nerve
head and the macula. Multicolor (MC) imaging of modi-
fied five field sections of the retina (central, nasal, superior,
temporal, and inferior) in addition to retinal BAF was
completed for the right and left eyes of both participants,
using the Heidelberg confocal scanning ophthalmoscope.
Outcome measures for the SD-OCT imaging sequences
included peripapillary RNFL and macular retinal segmen-
tation volumes for RNFL, ganglion cell layer, inner plexi-
form layer (IPL), inner nuclear layer, outer plexiform
layer, and outer nuclear layer. For each individual partici-
pant, the volume and thickness of all retinal neuronal
layers for each eye were expressed as a ratio of the total
retinal volume and thickness for each eye. Because we sus-
pected that volumetric RNFL changes in our cohort would
reflect systemic changes of preclinical AD, we averaged
the ratio for each retinal neuronal cell layer across both
eyes. Additionally, we conducted preliminary analyses to
examine potential asymmetry between eyes and found no
asymmetry across retinal layers (all P , .171).
Additionally, the number count and summed surface
area (mm2) of retinal inclusion bodies identified via BAF
were compared between Ab2 and Ab1 groups. These in-
clusion bodies differ from the age-related extracellular
drusen that typically accumulate at the level of Bruch’s
membrane and the retinal pigment epithelium. Research
in both animal and human models suggest that these in-
clusion bodies contain fibrillar Ab [25,26,33], which is
characteristic of the neocortical Ab plaque deposits
found in preclinical AD [34]. The number and surface
area of inclusion bodies was summed across both eyes
for each participant. The precise locations of these inclu-
sion bodies were primarily identified via BAF (en face
orientation). Multicolor imaging, which uses individual
laser colors to characterize anatomic and pathologic detail
at different retinal depths, was used specifically to identify
and exclude microbleeds and to ensure that we did not
count artifacts within the a and b crescents surrounding
the optic nerve head. However, the inclusion bodies that
we identified with BAF are not easily visualized with
multicolor imaging. Similarly, these inclusion bodies are
very difficult to identify using SD-OCT imaging (coronalsections), appearing as faint white spots with poor delin-
eation of borders. Our independent raters reviewed SD-
OCT images to the best of their ability, relying on major
vessels as landmarks, and noting their observations on vi-
sual inspection. On BAF analysis, we excluded the 360-
degree region within 1 disc diameter from the center of
the optic disc and the 360-degree macula region within
1 disc diameter from the foveal center. This was done to
avoid including the area of hypopigmentation around the
optic nerve in participants with zone a and/or b crescents
and to avoid including age-related macular drusen. All
other remaining sections across the standard 1, 2.22,
3.45 mm Early Treatment of Diabetic Retinopathy Study
grid were included in these analyses. Individuals with
background diabetic retinopathy and retinal microbleeds
(identified via multicolor imaging) were excluded. Inclu-
sion bodies were identified via 100% consensus ratings
from a post-doctoral research fellow and board-certified
ophthalmologist. Both raters were blinded to participant
amyloid status. See Fig. 1 for an example of identified
retinal inclusion bodies.
Surface area of inclusion bodies was measured using the
semi-automated Heidelberg Region Finder tool on the BAF
images obtained for each eye [35]. This tool allows the oper-
ator to place a ‘seed’ in the area of interest, and the software
automatically delineates the boundary of the object (in this
case, the inclusion bodies as shown in Fig. 1). On visual in-
spection, the operator has the ability to modify the bound-
aries, and then surface area is computed automatically and
recorded.
1.4. Data analysis
For each neuropsychological outcome measure, perfor-
mance between Ab1 and Ab2 groups was compared us-
ing a series of one-way analyses of variance (ANOVAs),
and the magnitude of differences was quantified using Co-
hen’s d. Although age was not significantly different be-
tween groups, it is a key predictor of volumetric loss in
the retina. As such, the volumes of retinal layers were
compared between the Ab1 and Ab2 groups with a se-
ries of analyses of covariance (ANCOVAs) with age as
the only covariate. We applied the false discovery rate
(FDR) approach to correct for multiple comparisons
[36]. Additionally, a linear regression model covarying
for age was used to examine the relationships between
surface area of inclusion bodies and cortical Ab burden
(SUVr). Correlations between number and surface area
of inclusion bodies and retinal layer volumes were
computed using Pearson’s r.2. Results
2.1. Demographic and clinical characteristics
Table 1 summarizes the demographic and clinical charac-
teristics of the study sample. Of the 63 participants, 10
Fig. 1. Inclusion bodies (circled in red ellipses) identified via BluePeak autofluorescence (BAF) imaging in a high neocortical amyloid-beta load (Ab1) cogni-
tively normal older adult.
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statistically significant differences between the Ab2 and
Ab1 groups on any demographic variables or any
neuropsychological assessments, with the exception of a
small but statistically significant difference (Ab1 , Ab2)
on the One-Card Learning task, a test of working memory
(Table 1).2.2. Effect of Ab on retinal layer volumes
Differences between Ab2 and Ab1 groups on the
volume of each retinal layer are summarized in
Table 2. The Ab1 group had higher volume in the innerTable 2
Differences in each retinal neuronal layer between low neocortical amyloid-beta lo
older adults
Retinal layer Age, df (F) P Amyloid, df (F) P
RNFL volume (1.60) 0.06 .811 (1.60) 1.56 .216
GCL volume (1.60) 0.60 .441 (1.60) 0.29 .595
INL volume (1.60) 0.05 .828 (1.60) 0.11 .745
IPL volume (1.60) 0.25 .622 (1.60) 4.98 .029
ONL volume (1.60) 0.01 .924 (1.60) 1.03 .315
OPL volume (1.60) 0.82 .369 (1.60) 0.69 .410
Inclusion bodies volume (1.55) 2.17 .146 (1.55) 2.59 .113
Abbreviations: Pf, P value after adjustment for false discovery rate (FDR; Ben
layer; GCL, ganglion cell layer; ONL, outer nuclear layer; IPL, inner plexiform l
Note. Volume/thickness of all layers has been normed to total retinal volume/thplexiform layer (IPL; mean [SD] 5 0.371 [0.028] mm3) in
comparison with the Ab2 group (mean [SD] 5 0.354
[0.028] mm3; Table 2, Fig. 2). However, this difference
was not statistically significant after controlling for mul-
tiple comparisons using FDR correction (see Table 2).
The Ab1 group also showed moderate increases in the
volume of the retinal nerve fiber layer (RNFL), but this
was not significantly different from the Ab2 group
(Fig. 2). Although we endeavored to compare our volume
measurements for the IPL to a comparable normative
sample, we were unable to identify a published normative
database that reports isolated IPL segmentation in an
older adult sample of healthy control subjects. Hence,ad (Ab2) and high neocortical amyloid-beta load (Ab1) cognitively normal
Pf Ab2 (n 5 53), mean (SD) Ab1 (n 5 10), mean (SD)
.504 0.073 (0.001) 0.077 (0.003)
.694 0.188 (0.003) 0.193 (0.008)
.745 0.166 (0.051) 0.124 (0.119)
.203 0.115 (0.001) 0.122 (0.003)
.551 0.218 (0.003) 0.226 (0.007)
.574 0.097 (0.002) 0.100 (0.004)
.400 2.850 (0.618) 5.485 (1.493)
jamini & Hochberg, 1995); OPL, outer plexiform layer; INL, inner nuclear
ayer; RNFL, retinal nerve fiber layer.
ickness for each individual participant. Values reported are ratios.
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Fig. 2. Magnitude of difference between low neocortical amyloid-beta load (Ab2) and high neocortical amyloid-beta load (Ab1) cognitively normal older
adults on each retinal neuronal layer and the number of inclusion bodies (“0” line represents Ab2 cognitively normal older adults group) (error bars represent
95% confidence intervals).
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we compared our measures of RNFL thickness to well-
established published normative data. A recent meta-
analysis of 17 OCT studies compared RNFL thicknesses
between patients with AD and older adult control sub-
jects (with measurements from 790 control eyes) [18].
Across these 17 studies, the mean RNFL thickness
ranged between 75 mm (SD 5 3.8) and 113.16 mm
(SD 5 6.72). For our total sample of subjects, we found
an overall mean RNFL thickness (both eyes) of
111.65 mm (SD 5 4.3), which falls within the range of
reported values for these other studies [18]. Hence, we
have reasonable confidence in our measures for other
retinal layers reported herein, including the IPL.Fig. 3. Relationship between surface area of inclusion bodies and amyloid-
beta (Ab) burden (dotted lines represent 95% confidence intervals).2.3. Effect of Ab on inclusion bodies
Relative to the Ab2 group, the Ab1 group showed a
larger surface area of inclusion bodies identified with
BAF imaging; however, although this difference was
moderate in magnitude, it was not large enough to reach
statistical significance (Fig. 2). When Ab burden was
treated continuously in the complete sample, there was
a significant relationship of a moderate magnitude be-
tween SUVr and surface area of inclusion bodies
(Fig. 3). Linear regression with age as a covariate showed
that surface area of inclusion bodies was a significant
predictor of SUVr (F(2, 31) 5 4.83, P , .05), accounting
for 22.5% of SUVr variance.2.4. Relationship between inclusion bodies and retinal
layer volumes
A significant relationship (r 5 0.41, P 5 .03) was iden-
tified between surface area of inclusion bodies and the vol-
ume of the IPL (Fig. 4A). This relationship existed despite
the trend toward decreased IPL volume with increasing age
(r 5 20.30, P 5 .08). There were no significant
Fig. 4. Relationship between surface area of inclusion bodies and the volume of the inner plexiform layer (A) and the outer plexiform layer (B) (dotted lines
represent 95% confidence intervals).
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the volume of any other retinal layer (Fig. 4B; all
P’s . .17). Moreover, using the HE Region Finder tool
with the cross-sectional OCT imaging, the majority of these
inclusion bodies were located within the IPL or adjacent to
the IPL, and the vast majority of these also appeared to be in
close proximity to microvessels.3. Discussion
This study used SD-OCT with BAF to examine retinal
biomarkers of preclinical AD. Our results show that, in
CN older adults who are at-risk for AD due to high levels
of CNS amyloid that: (1) surface area of retinal inclusion
bodies increased as a function of neocortical Ab accumu-
lation; (2) Ab1 older adults show increased thickness se-
lective to the IPL relative to Ab2 older adults. Although
the effect size difference between these two groups is
large (Cohen’s d 5 0.80), this difference did not reach
statistical significance due to small sample size for the
Ab2 group (N 5 10); and (3) IPL volume is associated
with increased total surface area of retinal inclusion
bodies.
The association between neocortical Ab deposition and
the surface area of retinal inclusion bodies adds to an ex-
panding body of literature demonstrating that pathologic
changes associated with early AD can be visualized in
the retina. From as early as the fourth week of gestation,
the eyes, particularly the RNFL and the optic nerve, are
direct sensory extensions of the central nervous system,
as their axons synapse directly with several brain regions.
The insoluble aggregates of Ab plaques and neurofibrillary
tangles in the brain that underlie the pathologic cascade of
AD can also be detected in the retinae of both living and
post mortem AD patients [37,38]. Accordingly, it has
been posited that the presence of Ab plaques andneurofibrillary tangles may contribute to ocular changes
such as RNFL thinning and associated optic nerve head
cupping, and changes within the lens and blood vessel
that have been observed in AD patients [15,19,39–41].
Kayabasi et al. used OCT to examine retinal changes in
Ab in patients with MCI. They visualized retinal Ab by
injecting curcumin, a ligand that putatively binds
selectively to fibrillar Ab, and found more inclusion
bodies in the plexiform retinal layers of MCI patients
than healthy controls [41]. This study builds on these find-
ings using SD-OCTwith BAF (a noninvasive technique) to
visualize inclusion bodies. In this study, we have extended
these findings from symptomatic patients with MCI [41] or
AD [37,38] to our participants with subjective memory
complaint and a first-degree family history of AD, that
is, a population at-risk for AD. It is important to note
that findings of retinal Ab in symptomatic AD patients
have been mixed, with several postmortem studies failing
to reveal significant retinal amyloid deposition in AD pa-
tients [42,43]. However, our findings support the
hypothesis that retinal biomarkers could be a useful
screening tool to distinguish individuals at risk for
developing AD and could be helpful in identifying ideal
candidates for secondary prevention trials.
Our principal finding is that the surface area (mm2) ac-
counted for by the retinal inclusion bodies that largely
appear within (or adjacent to) the IPL, and are mostly
observed for the Ab1 group, is moderately correlated
with neocortical amyloid burden across the entire series
of 63 subjects. Moreover, there was an additional positive
correlation observed between the surface area of these in-
clusion bodies and the thickness of the IPL layer (and this
relationship was not observed for any other neuronal
layer). Finally, it was only the IPL that showed a robust
increase in thickness for the Ab1 group relative to the
Ab2 group, although this difference failed to reach
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Ab2 group (N 5 10). The IPL is where bipolar and ama-
crine cells synapse with the dendrites of the ganglion
cells. In several species, markers for cholinergic synapses
are concentrated in the IPL, and acetylcholine is released
by distinct assemblies of amacrine and possibly bipolar
cells [44,45]. Moreover, immunohistochemistry using
acetylcholinesterase and choline acetyltransferase
(ChAT) as markers has revealed discrete bands of
cholinergic activity within the IPL in lampreys [46], am-
phibians [47], rodents [48,49], nonhuman primates [49],
and humans [49]. Although we acknowledge that symp-
tomatic AD patients have shown a thinning of the
RNFL [19,41], in contrast to our current findings in the
preclinical population, we hypothesize that the finding
that the cholinergic-rich IPL seems to be the central
neuronal layer affected in our population is important
and specific to a preclinical AD population. A disruption
to the cortical cholinergic system is one of the most reli-
able and earliest neurochemical changes in AD [50].
Recent imaging studies of the cortical cholinergic system
in living AD patients have supported an early cholinergic
disruption [51,52]. Additionally, in vivo and in vitro
animal work has shown that decreased activation of
cholinergic receptors leads to increased Ab burden [53–
56]. Finally, postmortem histopathological studies have
revealed decreased ChAT activity in nonsymptomatic
participants in areas with high Ab burden [53,57].
Taken together, this work indicates that cholinergic
disruption and Ab deposition in the neocortex co-occur
in preclinical AD. The finding of increased volume in
the cholinergic-rich IPL in the Ab1 group associated
with increased surface area of retinal inclusion bodies
(thought to contain Ab) suggests that a similar process
could be occurring in the retina in this group of at-risk
AD patients. It is possible that these retinal changes
represent an early inflammatory process occurring in
the major cholinergic center of the retina that parallels
the early pathologic cascade of AD in the neocortex, in
which early cholinergic changes co-occur with Ab depo-
sition in the major cholinergic centers of the brain. How-
ever, this hypothesis is tentative and requires replication
and further investigation in larger cohorts to ensure
greater statistical power and confidence.
Our study has several limitations. First, there is no
conclusive postmortem histopathology confirming the
presence of fibrillar Ab in the inclusion bodies identified
in this study. Although there are histopathologic studies
confirming the presence of Ab in inclusion bodies
[25,26], confirmation by within-subjects study design
has not been completed to date. Future longitudinal inves-
tigations should attempt to include postmortem histopa-
thology to confirm the presence of fibrillar Ab in the
same type and conformation of inclusion bodies that we
found in the majority of our Ab1 subjects (Fig. 1).
Furthermore, because the SPECTRALIS system usesnew technology and an advanced segmentation algorithm,
normative volumetric data on finely segmented retinal
layers, specifically the IPL, were not available at the
time of publication. Development of these normative
data as this technology becomes more widely available
will be critical in the assessment of retinal correlates of
preclinical AD. Additionally, our sample sizes are rela-
tively small, with 10 Ab1 and 53 Ab2 participants.
Despite the small sample of Ab1 participants, these initial
results are promising and provide foundation for future
detailed exploration of the relationship between neocor-
tical and retinal disease burden in preclinical AD. We
plan to follow these participants longitudinally to visu-
alize within-subjects changes in retinal and cortical bio-
markers associated with disease progression. Along with
longitudinal analysis, replication of this study will be
the next step in validating these retinal biomarkers of pre-
clinical AD and further examining the retinal cholinergic
hypotheses generated from these results.
These limitations notwithstanding, our results show
that SD-OCT imaging of the retina may allow for the pre-
diction of neocortical amyloid burden. This is the first
study to demonstrate these results in a preclinical AD
population, using a noninvasive imaging technique. Addi-
tionally, the preclinical stage of AD may be associated
with increased volume of the inner plexiform layer of
the retina, and this volume increase is correlated with
increased presence of neocortical Ab. This IPL volume
increase could reflect an early inflammatory process
related to disruption of cholinergic transmission that co-
occurs with Ab deposition in the neocortex and/or be a
result of these inclusion bodies occupying space within
(and adjacent to) this retinal layer. These preliminary re-
sults indicate that SD-OCT imaging of these early
changes in the retina in preclinical AD patients could
provide a more cost-effective method of examining bio-
markers that are indicative of disease burden and reflec-
tive of time-specific changes in the neocortex.Acknowledgments
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1. Systematic review: The authors review current state
of knowledge with respect to nonvascular retinal im-
aging markers of early Alzheimer’s disease (AD) and
describe the conduct of a cross-sectional study of
individuals at high risk for AD, with a subset of these
individuals identified as falling within the preclinical
stage of the disease. This study compares neocortical
beta-amyloid aggregation (PET imaging) to retinal
spectral domain optical coherence tomography (SD-
OCT) markers of possible disease burden in the
preclinical stage of AD.
2. Interpretation: Using blue-light autoflourescence
imaging, inclusion bodies were found in individuals
with significant neocortical amyloid burden, and
these were absent in the retinal imaging of in-
dividuals without substantial beta-amyloid aggrega-
tion. The surface of these inclusion bodies increased
as a function of cortical amyloid burden. Addition-
ally, there was a trend toward a selective volume
increase in the inner plexiform layer (IPL; a layer
rich in cholinergic activity) of the retina, in amyloid-
positive participants, and IPL volume was correlated
with the surface area of the same retinal inclusion
bodies.
3. Future directions: If these findings are replicated,
these retinal imaging markers may eventually lead
to a potential cost-effective and noninvasive tech-
nique that can be used to identify those at-risk for AD.
Layer-specific changes in the IPL and their associa-
tion with surface area of inclusion bodies are dis-
cussed as a possible reflection of early inflammatory
processes associated with cholinergic disruption and
concurrent Ab accumulation in the neocortex.
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